Recent advances in adjuvant systemic therapy for early-stage breast cancer

Annals of Oncology

Volumn 19, Issue SUPPL. 5, 2008, Pages

  Bedard, P L ^a   Cardoso, F ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LETROZOLE; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TAXOID;

ADJUVANT THERAPY; ARTHRALGIA; ARTHROPATHY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG WITHDRAWAL; EARLY CANCER; FEBRILE NEUTROPENIA; HUMAN; LETHARGY; LYMPH NODE METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUROPATHY; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CANCER STAGING; FEMALE; PATHOLOGY; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASM STAGING; TAXOIDS;

EID: 49049103623     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn325     Document Type: Conference Paper

References (57)

1. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Verdecchia A, Francisci S, Brenner H et al. Recent cancer survival in Europe: A 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-796.
3. Bria E, Nistico C, Cuppone F et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer. Cancer 2006; 106: 2337-2344.
4. De Laurentiis M, Cancello G, D'Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 2008; 26: 44-53.
5. Ferguson T, Wilcken N, Vagg R et al. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews 2007; (Issue 4):.
6. Peto R et al. Early Breast Cancer Trialists' Collaborative Group. The worldwide overview: New results for systemic adjuvant therapies. San Antonio Breast Cancer Symposium 2007 Abstr P-1.
7. Burnell M, Levine M, Chapman J et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of an interim analysis. San Antonio Breast Cancer Symposium 2006 Abstr 53.
8. Burnell MJ, Levine MN, Chapman JA et al. A phase III adjuvant trial of sequenced EC + filgrastim + epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or highrisk node-negative breast cancer (NCIC CTG MA.21). Proc Am Soc Clin Oncol 2007; 25: 550.
9. Ellis P, Barrett-Lee P, Bloomfield D et al. Preliminary results of the UK Taxotere as Adjuvant Chemotherapy (TACT) Trial. San Antonio Breast Cancer Symposium 2007 Abstr 78.
10. Hayes DF, Thor AD, Dressler LG et al. HER2 and response to paclitaxel in nodepositive breast cancer. New Engl J Med 2007; 357: 1496-1506.
11. Jacquemier J, Penault-Llorca F, Mnif H et al. Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA). American Society of Clinical Oncology Annual Meeting 2006 Abstr 509.
12. Rodríguez-Lescure A, Martín M, Ruiz A et al. Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECP): Relevance of HER2 and hormonal status (HR). American Society of Clinical Oncology Annual Meeting 2007 Abstr 10598.
13. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
14. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
15. (EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
16. Poole CJ, Earl HM, Hiller L et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. New Engl J Med 2006; 355: 1851-1862.
17. Sparano JA, Wang M, Martino S et al. Phase III study of doxorubicin- cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: Results of Intergroup Trial E1199. American Society of Clinical Oncology Annual Meeting 2007 Abstr 516.
18. Seidman AD, Berry D, Cirrincione C et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. American Society of Clinical Oncology Annual Meeting 2004 Abstr 512.
19. Verrill MW, Lee J, Cameron DA et al. Anglo-Celtic IV: First results of a UK National Cancer Research Network randomised phase 3 pharmacogenetic trial of weekly versus 3 weekly Paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). American Society of Clinical Oncology Annual Meeting 2007 LBA 1005.
20. Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-5551.
21. Doyle JJ, Neugut AI, Jacobson JS et al. Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. J Clin Oncol 2005; 23: 8597-8605.
22. Giordano SH, Duan Z, Kuo Y-F et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006; 24: 2750-2756.
23. Jones S, Holmes F, O'Shaughnessy J et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: Docetaxel/ cyclophosphamide is associated with an OS benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. San Antonio Breast Cancer Symposium 2007 Abstr 12.
24. Jones SE, Savin MA, Holmes FA et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006; 24: 5381-5387.
25. Gennari A, Sormani MP, Pronzato P et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 2008; 100: 14-20.
26. Slamon D, Eirmann W, Robert N et al. BCIRG 066: Second Interim Analysis Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Breast Cancer Res Treat 2006; 100 (Suppl 1): Abstr 52.
27. Press M, Bernstein L, Sauter G et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. Breast Cancer Res Treat 2006; 100 (Suppl 1): Abstr 1045.
28. Slamon D, Mackey J, Robert N et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: Efficacy analyses determined by molecular subtypes of the disease. San Antonio Breast Cancer Symposium 2007 Abstr 13.
29. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. New Engl J Med 2005; 353: 1734-1736.
30. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 2005; 353: 1673-1684.
31. Piccart-Gebhart W, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New Engl J Med 2005; 353: 1659-1672.
32. Slamon D, Eiermann W, Robert N et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: First interim efficacy analysis. San Antonio Breast Cancer Symposium 2005 Abstr 1.
33. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. New Engl J Med 2006; 354: 809-820.
34. Perez EA, Romond EH, Suman VJ et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/ without trastuzumab in patients with HER2-positive breast cancer. 2007 ASCO Annual Meeting Proceedings Part I 2007; 25(18S): 512.
35. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 2008; 369: 29-36.
36. Spielmann M, Roché H, Humblet Y et al. 3-year follow-up of trastuzumab following adjuvant chemotherapy in node positive HER2-positive breast cancer patients: Results of the PACS-04 trial. San Antonio Breast Cancer Symposium 2007.
37. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-2746.
38. Pritchard KI. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen. J Clin Oncol 2005; 23: 4850-4852.
39. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Engl J Med 2003; 349: 1793-1802.
40. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684-690.
41. Peto R, Davies C. on behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results. San Antonio Breast Cancer Symposium 2007 Abstr 48.
42. Effect of anastrazole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
43. Sestak I, Cuzick J et al. ATAC Trialists' Group. Risk factors for joint symptoms in the ATAC trial. San Antonio Breast Cancer Symposium 2007 Abstr 2071.
44. Renshaw L, McHugh M, Williams L. Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole. San Antonio Breast Cancer Symposium 2007 Abstr 2072.
45. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: Highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18: 1133-1144.
46. Dowsett M, Cuzick J, Wale C at al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Clin Oncol 2005; 23: 7512-7517.
47. Cui X, Schiff R, Arpino G et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy, J Clin Oncol 2005; 23: 7721-7735.
48. Dowsett M, Allred C, Knox J et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex. Tamoxifen, Alone or in Combination Trial. J Clin Oncol 2008; 26: 1059-1065.
49. The Breast International Group 1-98 Collaborative G. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med 2005; 353: 2747-2757.
50. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462.
51. Viale G, Giobbie-Hurder A. researchers from the BIG 1-98 Collaborative Group and International Breast Cancer Study Group (IBCSG). Value of centrally-assessed Ki-67 labeling index as a marker of prognosis and predictor of response to adjuvant endocrine therapy in the BIG 1-98 trial of postmenopausal women with estrogen receptor-positive breast cancer. San Antonio Breast Cancer Symposium 2007 Abstr 64.
52. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-9318.
53. Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patent CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-5193.
54. Lim H-S, Ju Lee H. Sook Lee K et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007; 25: 3837-3845.
55. Rae J, Sikora M, Henry N et al. Cytochrome P450 2D6 activity predicts adherence to tamoxifen therapy. San Antonio Breast Cancer Symposium 2007 Abstr 77.
56. Bonanni B, Maisonneuve P, Johansson H et al. Risk stratification based on the CYP2D6 tamoxifen metabolizing gene within the Italian tamoxifen preventon trial. San Antonio Breast Cancer Symposium 2007 Abstr 29.
57. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.